Fresh from its successful IPO in Hong Kong, AI-driven biotech Insilico Medicine has kicked off the year by entering an oncology discovery and development partnership with French pharmaceutical giant Servier.
Deal structure and corporate roles The collaboration is valued at up to $888 million in total potential payments. Insilico is set to receive approximately $32 million through a combination of upfront and R&D-related fees. The primary objective is to leverage Insilico’s proprietary AI platform, Pharma.AI, to identify and design novel drugs for “challenging targets” in cancer research.
-
Insilico Medicine: Will lead the AI-driven discovery and development phases.
-
Servier: Will share R&D expenses and take the lead on clinical validation and future commercialization efforts.
Insilico’s growth momentum This deal was announced less than a week after Insilico began trading on the Hong Kong Stock Exchange, raising $293 million. In 2025, the company secured several high-profile partnerships, including a pact with Eli Lilly worth over $100 million. Since its founding in 2014, Insilico has pioneered the use of generative AI to design molecular drug candidates for various conditions, including fibrosis and longevity.
Servier’s expansion strategy For Servier, the partnership with Insilico aligns with its 2030 vision of becoming an innovative, patient-centric pharma leader focused on three pillars: oncology, cardiometabolism, and neurology. This follows other significant recent investments by the French firm, including deals with Kaerus Bioscience and Ideaya Biosciences to bolster its clinical-stage pipeline.